Atlas Trials

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Clinical trial NCT04660539 · COMPLETED

Trial details

NCT number
NCT04660539
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Neuromyelitis Optica Spectrum Disorder
Start date
2021-03-02
Primary completion
2024-05-28
Enrollment
119

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.